CRISPR Therapeutics AG logo
CRISPR Therapeutics AG CRSP
$ 48.75 -0.25%

Annual report 2025
added 02-12-2026

report update icon

CRISPR Therapeutics AG Accounts Payables 2011-2026 | CRSP

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.
Main types of accounts payable
Type of liabilityExample
To suppliers and contractorsGoods received but not yet paid for
Taxes and feesVAT, income tax, etc., not paid on time
SalariesEmployee wages not paid
To budgetsInsurance contributions to funds not paid
To foundersFounders provided borrowed funds
To banksOverdue loan payments
OtherFines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance
  1. Liquidity and solvency
    Accounts payable are part of short-term liabilities, so they affect liquidity ratios
  2. Financial stability
    The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
  3. Capital turnover
    Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
  4. Risks and reputation
    Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables CRISPR Therapeutics AG

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
11.1 M 14.7 M 38.1 M 27.4 M 14.8 M 9.09 M 5.94 M 5.07 M 1.64 M 4.57 M - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
38.1 M 1.64 M 13.3 M

Quarterly Accounts Payables CRISPR Therapeutics AG

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
11.8 M 9.75 M 13.1 M 14.7 M 15.6 M 9.45 M 16.5 M 38.1 M 26.2 M 27.6 M 45.2 M 27.4 M 32.1 M 25.2 M 27.1 M 14.8 M 10.2 M 10.1 M 13.1 M 9.09 M 9.09 M 9.09 M 9.09 M 5.94 M 5.94 M 5.94 M 5.94 M 5.07 M 5.07 M 5.07 M 5.07 M 1.64 M 1.64 M 1.64 M 1.64 M 4.57 M 4.57 M 4.57 M 4.57 M 1.58 M 1.58 M - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
45.2 M 1.58 M 12.1 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer Accounts Payables Price % 24h Market Cap Country
Aptorum Group Limited Aptorum Group Limited
APM
3.24 M $ 0.79 -1.15 % $ 4.31 M chinaChina
Acorda Therapeutics Acorda Therapeutics
ACOR
13.4 M - -24.86 % $ 820 K usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
1.65 M - - $ 528 M usaUSA
I-Mab I-Mab
IMAB
570 M - - $ 866 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
1.41 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
677 K - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
2.91 M - - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
9.03 M - - $ 3.67 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
1.61 M - - $ 86.2 M usaUSA
Akouos Akouos
AKUS
1.28 M - 0.23 % $ 488 M usaUSA
Advaxis Advaxis
ADXS
6.08 M - -9.65 % $ 45.9 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
1.03 M - 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
911 K - 10.36 % $ 9.8 M usaUSA
BioCardia BioCardia
BCDA
890 K $ 1.26 -0.79 % $ 26.7 M usaUSA
AlloVir AlloVir
ALVR
247 K - 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
1.58 M - - $ 10.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
9.86 M $ 14.2 -0.7 % $ 208 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
1.26 M - -45.71 % $ 1.2 M canadaCanada
Acer Therapeutics Acer Therapeutics
ACER
3.81 M - 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
3.46 M - 1052.0 % $ 415 M usaUSA
Athersys Athersys
ATHX
9.16 M - 3.77 % $ 22.4 M usaUSA
Aptinyx Aptinyx
APTX
724 K - -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
155 K - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
1.97 M $ 1.44 -1.37 % $ 367 M britainBritain
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
4.24 M $ 6.68 -4.57 % $ 183 M israelIsrael
Acasti Pharma Acasti Pharma
ACST
601 K - 4.01 % $ 150 M canadaCanada
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
2.71 M - - $ 521 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
4.08 M - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
10.6 M $ 2.54 -5.22 % $ 16 M usaUSA
Certara Certara
CERT
3.43 M $ 6.67 1.6 % $ 1.07 B usaUSA
Athira Pharma Athira Pharma
ATHA
319 K - - $ 269 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
561 K $ 3.6 -4.0 % $ 7.83 B israelIsrael
Aravive Aravive
ARAV
8.76 M - -13.39 % $ 1.45 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
6.08 M - -2.5 % $ 5.88 M usaUSA